Abstract: Central precocious puberty is the premature activation of the hypothalamic-pituitary-gonadal axis, leading to an early epiphyseal fusion and, in many cases, heights below the genetic target. Therefore, a proper adult stature prediction is essential for the treatment decision. Objective: To compare the concordance of final height using height prediction made by two validated methods versus the ge netic target height in girls who consulted due to central precocious puberty. Patients and Method: Retrospective, non-concurrent cohort study including 93 girls with central precocious puberty, who were not treated with LHRH analogs and had reached their final adult height. The data was obtained from the clinical records. To predict height, the Bayley-Pinneau method and the Roche-Wainer- Thissen method were applied, and the results were compared with the genetic target height. The concordance between the estimated final height and the final height obtained was evaluated using the Bland-Altman method. Results: When comparing the final height obtained with that predicted by the Bayley-Pinneau method, there was a mean difference of 1.01 cm, and using the Rocke-Wainer-Thissen method, there was a difference of +0.96 cm. The calculation of the genetic target height showed a difference of +0.05 cm with respect to the final height. Conclusion: The prediction of height made by the Bayley-Pinneau and Roche-Wainer-Thissen methods was adequate and, contrary to expectations, it was similar to the calculation of the genetic target height that does not use the age of bone maturation. This also presented better concordance and less dispersion of the results with respect to the final height obtained.

Resumen: La pubertad precoz central consiste en una activación prematura del eje hipotálamo-hipófisis-gonadal, lo que produce una fusión temprana del cartílago de crecimiento y, en muchos casos, una talla inferior al objetivo genético. Un adecuado pronóstico de estatura final es fundamental para definir el tratamiento. Objetivo: Comparar la concordancia de la talla final utilizando la predicción de la esta tura efectuada por dos métodos validados versus la talla diana o talla objetivo genético, en niñas que consultaron por pubertad precoz central. Pacientes y Método: estudio retrospectivo de cohorte no concurrente en el que participaron 93 niñas con pubertad precoz central no tratadas con análogos de LHRH y que alcanzaron su talla final. Los datos iniciales se obtuvieron de sus fichas clínicas. Para pre decir la talla se aplicaron los métodos más utilizados en la práctica clínica, Bayley-Pinneau y Roche- Wainer-Thissen, y luego se compararon los resultados con la talla objetivo genético. La concordancia entre la talla final estimada y la talla final obtenida se evaluó mediante el método de Bland y Altman. Resultados: Al comparar la talla final obtenida con la predicha por el método de Bayley-Pinneau se observó una diferencia promedio de 1,01 cm. Mediante el método de Roche-Wainer-Thissen, se observó una diferencia de +0,96 cm. El cálculo de la talla objetivo genético, arrojó una diferencia de +0,05 cm respecto a la talla final. Conclusión: La predicción de estatura realizada por los métodos Bayley-Pinneau y Roche-Wainer-Thissen fue adecuada, y contrario a lo esperado, fue similar al cálcu lo de la talla objetivo genético que no utiliza la edad de maduración ósea. Esta además presentó mejor concordancia y menor dispersión de los resultados respecto a la talla final obtenida.

ABSTRACT Objective Warthin-like papillary thyroid cancer (WL-PTC) is an uncommon variant of PTC, usually associated with lymphocytic thyroiditis. Scarce evidence suggests that WL-PTC has similar clinical presentation to classic PTC (C-PTC), with no studies comparing risks of recurrence and response to treatment between both variants. Our objective was to describe the clinical presentation and prognosis of WL-PTC and compare it to C-PTC. Subjects and methods Retrospective analysis of a prospective cohort, including 370 (96%) patients with C-PTC and 17 (4%) with WL-PTC, consecutively treated with total thyroidectomy with or without RAI, followed for at least 6 months. We compared clinical presentation, risk of mortality and recurrence, as well as response to treatment between both variants. Results Of the total cohort: 317 (82%) female, 38 ± 13.5 years, median follow-up 4 years (0.5-28.5); most of them stage I and low/intermediate risk of recurrence. We found no differences regarding clinical-pathological data and risk of recurrence. WL-PTC was associated with a higher rate of anti-thyroglobulin antibodies (TgAb) (65% vs. 36%, p = 0.016) and lymphocytic thyroiditis (59% vs. 34%, p = 0.03). The rates of biochemical and structural incomplete responses were similar in both variants. WL-PTC had a lower rate of excellent response (23% vs. 54%, p = 0.01), which became non-significant when performing analysis by TgAb presence (50% vs. 67%, p = NS). Conclusions WL-CPT and C-CPT have similar clinical presentation and rate of recurrence. The lower rate of excellent response to treatment in WL-PTC is due to a higher frequency of TgAb. WL-PCT should not be considered an aggressive variant of PTC.